1. 1) Imtiaz, B., Tolppanen, A.M., Kivipelto, M. and Soininen, H. (2014) Future direction in Alzheimer’s disease from risk factors to prevention. Biochem. Pharmacol. 88, 661–670.
2. 2) Selkoe, D.J. and Schenk, D. (2003) Alzheimer’s disease: Molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545–584.
3. 3) Querfurth, H.W. and LaFerla, F.M. (2014) Alzheimer’s disease. N. Engl. J. Med. 362, 329–344.
4. 4) Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M. (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 370, 322–333.
5. 5) Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S. (2014) Phase 3 trials of solanezmab for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 370, 311–321.